Vincrystine
Brand names,
Vincrystine
Analogs
Vincrystine
Brand Names Mixture
Vincrystine
Chemical_Formula
C46H56N4O10
Vincrystine
RX_link
http://www.rxlist.com/cgi/generic3/vincristine.htm
Vincrystine
fda sheet
Vincrystine
msds (material safety sheet)
Vincrystine
Synthesis Reference
No information avaliable
Vincrystine
Molecular Weight
824.958 g/mol
Vincrystine
Melting Point
220 oC
Vincrystine
H2O Solubility
No information avaliable
Vincrystine
State
Solid
Vincrystine
LogP
4.918
Vincrystine
Dosage Forms
Liquid; Solution
Vincrystine
Indication
For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis
Vincrystine
Pharmacology
Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific.
Vincrystine
Absorption
No information avaliable
Vincrystine
side effects and Toxicity
IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg
Vincrystine
Patient Information
PATIENT INFORMATION
Follow the links
http://www.rxlist.com/cgi/generic3/vincristine_wcp.htm
http://www.drugs.com/cons/Vincristine.html
Vincrystine
Organisms Affected
Humans and other mammals